Abstract
Therapy-related myelodysplasia (MDS) is a fatal marrow disorder distinct from primary MDS. We examined the efficacy of bone marrow transplantation (BMT) as a treatment for patients with therapy-related MDS. Eighteen patients with therapy-related MDS and twenty-five patients with primary MDS received an allogeneic, syngeneic, or unrelated donor BMT. Graft-versus-host disease prophylaxis included methotrexate, methotrexate plus cyclosporine, FK-506, or T cell depletion. Conditioning regimens consisted of cyclophosphamide/total body irradiation, with and without cytosine arabinoside, busulfan/cyclophos- phamide, and cyclophosphamide/etoposide/carmustine. For patients with therapy-related MDS, the median age was 32 years and the actuarial disease- free survival was 24% (95% confidence interval 6, 42%) with a median follow-up of 3 years. For patients with primary MDS, the median age was 36 years and the actuarial disease-free survival at 3 years was 43% (95% confidence interval 22, 64%). Four of the therapy-related patients and two of the primary patients have relapsed. Three patients experienced graft failure; all three had received T cell-depleted marrow and two had marrow fibrosis. Our results suggest that patients with therapy-related MDS can be successfully transplanted. Transplantation should be considered early in the disease, since long-term disease-free survival is achievable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ballen, K., Gilliland, D., Guinan, E. et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 20, 737–743 (1997). https://doi.org/10.1038/sj.bmt.1700971
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700971
Keywords
This article is cited by
-
Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients
Bone Marrow Transplantation (2015)
-
Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients
International Journal of Hematology (2010)
-
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML
Bone Marrow Transplantation (2008)
-
Die individualisierte Riskoeinschätzung und Therapieplanung bei myelodysplastischen Syndromen
Wiener klinische Wochenschrift (2008)
-
Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma
Bone Marrow Transplantation (2007)